TP53 and posterior cortical atrophy: Our study pioneers a "silencing-carrier synergy" design, leveraging EVs as protective and precision-guided vehicles for siRNA, while unveiling HSP60/p53 crosstalk as a metabolic vulnerability that bridges proteostasis and glycolytic addiction in PCa.